NEW YORK and LONDON, October 17, 2017 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announced that it intends to offer and sell, subject to market and other conditions, American Depositary Shares, or ADSs, in an underwritten public offering. In addition, Akari intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs sold in the offering, at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the ADSs in the offering are being sold by Akari. Akari intends to use the net proceeds from the offering to fund its ongoing research and clinical development efforts and for working capital and general corporate purposes.
AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE
Footer
Follow Us
